PrecisioBiotix

PrecisioBiotix is a biotechnology company focused on the development of precision-targeted oncology therapies through its proprietary virus-like drug conjugate (VDC) platform. The company was acquired by Aura Biosciences in August 2024 to enhance Aura's existing VDC capabilities and expand its pipeline into new solid tumor indications. PrecisioBiotix's technology utilizes virus-like particles to deliver cytotoxic payloads specifically to cancer cells while minimizing off-target effects on healthy tissue. Its lead research efforts are directed toward treating non-muscle invasive bladder cancer (NMIBC) and other high-unmet-need malignancies. The acquisition integrates PrecisioBiotix's early-stage assets and expertise into Aura's broader clinical development strategy.